Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS
- PMID: 27012525
- DOI: 10.1021/acs.analchem.5b03900
Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS
Abstract
Neonatal Fc receptor (FcRn) is the homeostatic receptor responsible for the long half-life of endogenous IgG by protecting it from lysosomal degradation. Understanding systemic FcRn tissue expression is important to predict and design the half-life of therapeutic antibodies and Fc-coupled biotherapeutics. To this end, we measured human FcRn (hFcRn) tissue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation of drug clearance to humans has been demonstrated. Building an hFcRn tissue expression profile in Tg32 was enabled by the development of a tissue preparation procedure composed of bead-based protein extraction and protein precipitation using acetone followed by pellet digestion with trypsin. Digests were then loaded onto an online peptide immuno-affinity flow configuration hyphenated with reversed phase nanoflow chromatography and coupled with high resolution mass spectrometry to quantify hFcRn derived peptides. The workflow allowed bypassing some of the challenges typically associated with membrane protein analysis. We demonstrated acceptable precision and bias for measuring hFcRn in tissue matrices, typically within 20% coefficient of variation and relative error. We also report hFcRn expression in several Tg32 tissues. We anticipate that establishing a quantitative approach for hFcRn in tissues will enable the systematic measurement of hFcRn concentrations to further increase the accuracy of physiologically based pharmacokinetic (PBPK) models for PK prediction of Fc-containing biotherapeutics. This is anticipated to improve the translation of pharmacokinetic data from preclinical model systems to humans.
Similar articles
-
Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.MAbs. 2016 Jul;8(5):848-53. doi: 10.1080/19420862.2016.1178436. Epub 2016 Apr 22. MAbs. 2016. PMID: 27104806 Free PMC article.
-
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27. MAbs. 2016. PMID: 27232760 Free PMC article.
-
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Xenobiotica. 2014 Dec;44(12):1127-34. doi: 10.3109/00498254.2014.941963. Epub 2014 Jul 17. Xenobiotica. 2014. PMID: 25030041
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2. Mol Immunol. 2013. PMID: 23917469 Review.
Cited by
-
The Neonatal Fc Receptor (FcRn): A Misnomer?Front Immunol. 2019 Jul 10;10:1540. doi: 10.3389/fimmu.2019.01540. eCollection 2019. Front Immunol. 2019. PMID: 31354709 Free PMC article. Review.
-
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):339-359. doi: 10.1007/s10928-019-09640-9. Epub 2019 May 11. J Pharmacokinet Pharmacodyn. 2019. PMID: 31079322
-
Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.Drug Metab Dispos. 2020 Oct;48(10):925-933. doi: 10.1124/dmd.120.000075. Epub 2020 Jul 28. Drug Metab Dispos. 2020. PMID: 32723849 Free PMC article.
-
Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology.J Neuromuscul Dis. 2019;6(1):147-159. doi: 10.3233/JND-180357. J Neuromuscul Dis. 2019. PMID: 30614809 Free PMC article.
-
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.Gene Ther. 2022 Nov;29(10-11):608-615. doi: 10.1038/s41434-021-00300-7. Epub 2021 Nov 5. Gene Ther. 2022. PMID: 34737451 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources